Evidence map›Paper›PMID 40188404›Full record

ReviewInternal and emergency medicine2025

Management of acute pancreatitis in the "no man's land".

Antonio Amodio, Nicolò de Pretis, Giulia De Marchi, Pietro Campagnola, Salvatore Crucillà, Federico Caldart, Luca Frulloni

Abstract readReview
In one paragraph

Review in Internal and emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. MiR-324-5p mitigates experimental acute pancreatitis by suppressing Rock2 expression.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antonio AmodioUniversity of Verona, Verona, Italy. antonio.amodio@aovr.veneto.it.ORCID 0000-0002-7989-0610
Nicolò de PretisUniversity of Verona, Verona, Italy.
Giulia De MarchiUniversity of Verona, Verona, Italy.
Pietro CampagnolaUniversity of Verona, Verona, Italy.
Salvatore CrucillàUniversity of Verona, Verona, Italy.
Federico CaldartUniversity of Verona, Verona, Italy.
Luca FrulloniUniversity of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute pancreatitis (AP) is an inflammatory disease that can represent a challenge for clinicians, in fact, the early determination of its severity in the first 72 h is crucial for prognosis, recognizing the etiology and carrying out risk stratification to determine a more specific therapy. No accurate early prognostic scores for disease severity have been published, so the severity of AP often cannot be properly defined in the first few hours of the disease. This initial phase represents a "no man's land", in which there is no certainty in the stratification of the damage, prognosis is difficult to establish, therapy must be started promptly, although there is still no effective medical therapy against pancreatic enzymatic activation. Therefore, it is very difficult at this stage to make the correct decisions to achieve the best outcome for the patient with AP. Literature search was carried out using the PubMed database by entering early management of acute pancreatitis [title] or therapy of acute pancreatitis [title] and selecting the most relevant articles for the diagnosis and therapy of acute pancreatitis in clinical practice. This document provides suggestions on managing the key clinical decisions for patients suffering from AP before disease severity is defined, to achieve the best outcomes for patients with AP.

Indexed as

PancreatitisAcute DiseaseHumansPrognosisSeverity of Illness IndexAcute pancreatitisAetiologyCorrect diagnosisTherapy

Identifiers

PMID40188404
PMCPMC12331852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.